CA2685141A1 - New compounds 806 - Google Patents

New compounds 806 Download PDF

Info

Publication number
CA2685141A1
CA2685141A1 CA002685141A CA2685141A CA2685141A1 CA 2685141 A1 CA2685141 A1 CA 2685141A1 CA 002685141 A CA002685141 A CA 002685141A CA 2685141 A CA2685141 A CA 2685141A CA 2685141 A1 CA2685141 A1 CA 2685141A1
Authority
CA
Canada
Prior art keywords
chromen
dihydro
nicotinamide
amine
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002685141A
Other languages
English (en)
French (fr)
Inventor
Yevgeni Besidski
Inger Kers
Martin Nyloef
Lars Sandberg
Karin Skogholm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39876087&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2685141(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2685141A1 publication Critical patent/CA2685141A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002685141A 2007-04-23 2008-04-22 New compounds 806 Abandoned CA2685141A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91331207P 2007-04-23 2007-04-23
US60/913,312 2007-04-23
PCT/SE2008/050459 WO2008130320A2 (en) 2007-04-23 2008-04-22 Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain

Publications (1)

Publication Number Publication Date
CA2685141A1 true CA2685141A1 (en) 2008-10-30

Family

ID=39876087

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002685141A Abandoned CA2685141A1 (en) 2007-04-23 2008-04-22 New compounds 806

Country Status (23)

Country Link
US (2) US8143408B2 (OSRAM)
EP (1) EP2158198B1 (OSRAM)
JP (1) JP2010525056A (OSRAM)
KR (1) KR20100015827A (OSRAM)
CN (1) CN101687860B (OSRAM)
AR (1) AR066266A1 (OSRAM)
AU (1) AU2008241610B2 (OSRAM)
BR (1) BRPI0810354A2 (OSRAM)
CA (1) CA2685141A1 (OSRAM)
CL (1) CL2008001170A1 (OSRAM)
CO (1) CO6251361A2 (OSRAM)
EC (1) ECSP099706A (OSRAM)
IL (1) IL201309A0 (OSRAM)
MX (1) MX2009011364A (OSRAM)
MY (1) MY146662A (OSRAM)
NZ (1) NZ581353A (OSRAM)
PE (1) PE20090727A1 (OSRAM)
RU (1) RU2460730C2 (OSRAM)
SA (1) SA08290245B1 (OSRAM)
TW (1) TW200848037A (OSRAM)
UY (1) UY31046A1 (OSRAM)
WO (1) WO2008130320A2 (OSRAM)
ZA (1) ZA200907137B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8748623B2 (en) * 2009-02-17 2014-06-10 Syntrix Biosystems, Inc. Pyridinecarboxamides as CXCR2 modulators
JP2013508456A (ja) * 2009-10-26 2013-03-07 シグナル ファーマシューティカルズ， エルエルシー ヘテロアリール化合物の合成方法および精製方法
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
KR20120130104A (ko) 2010-02-01 2012-11-28 닛뽕 케미파 가부시키가이샤 Ｇｐｒ119 작동약
US8779149B2 (en) 2010-08-23 2014-07-15 Syntrix Biosystems, Inc. Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
WO2012039657A1 (en) * 2010-09-22 2012-03-29 Astrazeneca Ab Novel chromane compound for the treatment of pain disorders
CN102408385B (zh) * 2011-06-20 2014-06-18 雅本化学股份有限公司 一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法
CN102408386B (zh) * 2011-07-27 2014-05-07 雅本化学股份有限公司 2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法
CN102603659B (zh) * 2012-03-01 2014-03-26 雅本化学股份有限公司 1-取代-4-溴-1h-1,2,3-三氮唑-5-羧酸及其制备方法
KR102226587B1 (ko) * 2013-01-31 2021-03-11 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
KR20160118345A (ko) * 2014-02-06 2016-10-11 애브비 인코포레이티드 6-헤테로아릴옥시- 및 6-아릴옥시-퀴놀린-2-카복사미드 및 이의 용도
KR102412146B1 (ko) 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 소디움 채널 차단제
AU2016351526B2 (en) 2015-11-13 2019-02-21 In Therapeutics Sodium channel blocker
CN105541774B (zh) * 2016-01-13 2018-06-15 华中师范大学 3,4-二氢香豆素类化合物及其制备方法和用途
US11485733B2 (en) * 2017-06-30 2022-11-01 Bayer Animal Health Gmbh Azaquinoline derivatives
EP3740481B9 (en) 2018-01-19 2024-10-23 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
AU2019232437A1 (en) 2018-03-07 2020-10-08 Bayer Aktiengesellschaft Identification and use of ERK5 inhibitors
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
FI3851436T3 (fi) 2018-09-10 2024-09-03 Kaken Pharma Co Ltd Uusi heteroaromaattinen amidijohdannainen ja sitä sisältävä lääke
EP3972963A1 (en) 2019-05-21 2022-03-30 Bayer Aktiengesellschaft Identification and use of kras inhibitors
MX2023010125A (es) 2021-03-04 2023-09-11 Cytokinetics Inc Inhibidores del sarcomero cardiaco.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
WO1994012493A1 (en) * 1992-11-25 1994-06-09 Sandoz, Ltd. 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2h-1-benzopyr ans, their use as pharmaceuticals
JPH0827153A (ja) * 1994-07-12 1996-01-30 Nippon Kayaku Co Ltd アザクロマン誘導体及びその用途
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
GB9713804D0 (en) * 1997-06-30 1997-09-03 Novo Nordisk As Particulate polymeric materials and their use
JPH1135569A (ja) 1997-07-22 1999-02-09 Meiji Milk Prod Co Ltd ポリフェノール化合物及びこれを含有する医薬
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
SE9703378D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703377D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
TW200524888A (en) * 2003-08-08 2005-08-01 Vertex Pharma Compositions useful as inhibitors of voltage-gated ion channels
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
EP1877385A1 (en) * 2005-05-04 2008-01-16 Vertex Pharmaceuticals Incorporated Pyrimidines and pyrazines useful as modulators of ion channels
EP2044019A1 (en) * 2006-07-12 2009-04-08 Astra Zeneca AB 3-oxoisoindoline-1-carboxamide derivatives as analgesic agents
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم

Also Published As

Publication number Publication date
AU2008241610B2 (en) 2011-08-18
SA08290245B1 (ar) 2012-02-12
JP2010525056A (ja) 2010-07-22
US8143408B2 (en) 2012-03-27
EP2158198A2 (en) 2010-03-03
PE20090727A1 (es) 2009-07-23
AR066266A1 (es) 2009-08-05
CN101687860A (zh) 2010-03-31
IL201309A0 (en) 2010-05-31
RU2009138137A (ru) 2011-05-27
AU2008241610A1 (en) 2008-10-30
EP2158198B1 (en) 2013-03-20
MX2009011364A (es) 2009-11-05
US20100137322A1 (en) 2010-06-03
CL2008001170A1 (es) 2009-05-22
EP2158198A4 (en) 2012-01-04
CO6251361A2 (es) 2011-02-21
CN101687860B (zh) 2012-07-04
MY146662A (en) 2012-09-14
TW200848037A (en) 2008-12-16
ECSP099706A (es) 2009-11-30
WO2008130320A2 (en) 2008-10-30
NZ581353A (en) 2012-02-24
WO2008130320A3 (en) 2008-12-18
ZA200907137B (en) 2010-07-28
US20120238579A1 (en) 2012-09-20
UY31046A1 (es) 2008-11-28
BRPI0810354A2 (pt) 2014-10-21
RU2460730C2 (ru) 2012-09-10
KR20100015827A (ko) 2010-02-12

Similar Documents

Publication Publication Date Title
AU2008241610B2 (en) Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
AU2011205302B2 (en) Voltage-gated sodium channel blockers
CA2938855C (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
WO2008075172A2 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
CA2917193A1 (en) Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators
WO2012016217A1 (en) Ampk-activating heterocyclic compounds and methods for using the same
EP2794593B1 (en) Spiro aminic compounds as orexin antagonists
CA3189908A1 (en) Bicycloheptane pyrrolidine orexin receptor agonists
WO2005103043A1 (en) 2, 4, 6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer’s disease
WO2019063748A1 (en) INHIBITORS OF ROR-GAMMA
MX2010012067A (es) Derivados de 3,4-piperidina sustituida como inhibidores de la renina.
JP2023540548A (ja) 抗腫瘍活性を有する化合物及びその使用
EP2077719B1 (en) Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
JPWO2009119537A1 (ja) ヒドロキシキノキサリンカルボキサミド誘導体
KR102365673B1 (ko) 티아졸리디논 화합물 및 그의 용도
CA2940047A1 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
CN118715206A (zh) 新型hdac抑制剂及其治疗用途
WO2008130319A2 (en) Novel n-tetrahydronaphtalene or n-chromane carboxamide derivatives for the treatment of pain
TW202515851A (zh) Keap1抑制劑及其用途
WO2008130322A1 (en) Novel 5-heterocyclyl-chromane derivatives for the treatment of pain
WO2008130321A2 (en) Novel n-tetrahydronaphtalene or 5-heterocyclyl-chromane or 8-heterocyclyl-tetrahydronaphtalene derivatives for the treatment of pain
JP2011088888A (ja) ヒドロキシキノキサリンカルボキサミド誘導体を含有する医薬組成物
HK1219478B (zh) 用作trpa1调节剂的取代的杂环磺酰胺化合物

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140422